Oligodendroglioma Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032),| Key Companies – Teva Pharmaceuticals, AOI Pharmaceuticals Merck Pharmaceuticals, Pfizer

May 01 17:31 2023
Oligodendroglioma Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032),| Key Companies - Teva Pharmaceuticals, AOI Pharmaceuticals Merck Pharmaceuticals, Pfizer
DelveInsight Business Research LLP
DelveInsight’s “Oligodendroglioma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Oligodendroglioma, historical and forecasted epidemiology as well as the Oligodendroglioma market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

DelveInsight’s “Oligodendroglioma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Oligodendroglioma, historical and forecasted epidemiology as well as the Oligodendroglioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

 Oligodendroglioma Overview

Oligodendrogliomas are a type of glioma believed to originate from the brain’s oligodendrocytes or a glial precursor cell. They occur primarily in adults (9.4% of all primary brain and central nervous system tumors) but also in children (4% of all primary brain tumors).

 

Oligodendroglioma Epidemiology Insights

  • Oligodendroglioma is the third most common glioma, and it occurs primarily in adults constituting 9.4% of all primary brain tumors and 5% of all glial neoplasms. It can also be found in children. Oligodendroglioma and anaplastic oligodendroglioma, together, are one-tenth as joint as glioblastoma (the most commonly occurring malignant primary brain tumor in adults).

  • The incidence of oligodendroglioma and anaplastic oligodendroglioma is estimated to be 0.32 and 0.17 cases per 100,000 individuals in the United States, respectively. Approximately, 1000 oligodendroglial tumors are diagnosed each year in the United States.

  • Oligodendroglioma is a disease that tends to affect middle-aged adults (adults between 25 and 45 years of age). Oligodendroglioma most commonly occurs in the 4th and 5th decade of life. The median age at diagnosis of oligodendroglioma is 35-47 years.

  • Median age at diagnosis is approximately 5 to 10 years older for World Health Organization (WHO) grade III (anaplastic) tumors compared with WHO degree II (low-grade) tumors.

  • Oligodendroglioma is occasionally diagnosed in teenagers and adults over the age of 65 years.

  • Males are more commonly affected with oligodendroglioma than females. The male-to-female ratio is approximately 1.3:1.

  • Oligodendroglioma usually affects individuals of the Caucasian race. African American, Latin American, and Asian individuals are less likely to develop oligodendroglioma.

The Report Covers the Oligodendroglioma Epidemiology Segmented by:

  • Total Oligodendroglioma incident cases 

  • Total Oligodendroglioma prevalent cases 

  • Total Oligodendroglioma treatment cases 

  • Total Oligodendroglioma diagnostic cases 

  • Total Oligodendroglioma cases based on age 

  • Total Oligodendroglioma cases based on gender 

  • Total Oligodendroglioma cases based on race 

Oligodendroglioma Market Outlook 

The Oligodendroglioma market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Oligodendroglioma market trends by analyzing the impact of current Oligodendroglioma therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Oligodendroglioma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Oligodendroglioma market data are presented with relevant tables and graphs to give a clear idea of the market at first sight.

According to DelveInsight, the Oligodendroglioma market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Companies Working in the Oligodendroglioma Market

  • Teva Pharmaceuticals 

  • AOI Pharmaceuticals 

  • Merck Pharmaceuticals 

  • Pfizer 

And many others 

Oligodendroglioma Therapies Covered and Analyzed in the Report:

  •  RRx-001 

  •  Temozolomide 

  •  PF-06840003

  •  OKN-007

And many others 

Learn more about the Key Companies and Emerging Therapies in the Oligodendroglioma Market.

 Table of Contents 

  1. Key Insights 

  2. Oligodendroglioma  Introduction 

  3. Executive Summary of Oligodendroglioma   

  4. Disease Background and Overview

  5. Epidemiology and patient population

  6. Oligodendroglioma  Emerging Therapies

  7. Oligodendroglioma  Market Outlook

  8. Market Access and Reimbursement of Therapies

  9. Market Drivers 

  10. Market Barriers 

  11. Appendix

  12. Report Methodology

  13. DelveInsight Capabilities

  14. Disclaimer

Learn about the detailed offerings of the report @ Oligodendroglioma Market Outlook.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/